Clinical Trial Update: A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial of multiple-dose intravitreal GEM103 for neovascular age-related macular degeneration was terminated, with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration
• Retinal Degeneration
• Retinal Disease

Drugs mentioned

• GEM103 (GEM103)

Snippet

Sponsor: Gemini Therapeutics, Inc. | Conditions: Neovascular Age-related Macular Degeneration, Retinal Disease | Phase 2 | Status: TERMINATED | Results posted: 2022-10-31